Why Albany Molecular Research (AMRI) Is Down Today

NEW YORK (TheStreet) -- Albany Molecular Research  (AMRI) dropped on Friday after Sterne Agee downgraded the company to "underperform" from "neutral."

The firm evaluated the company's other assets and claimed "accretion does not appear robust enough to justify the current valuation," according to a research note. Sterne Agee maintained its $13 target price.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

----------

Separately, TheStreet Ratings team rates ALBANY MOLECULAR RESH INC as a "buy" with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate ALBANY MOLECULAR RESH INC (AMRI) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins."

AMRI Chart

AMRI data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders